Articles tagged with Nephritis
A nationwide intervention has led to increased kidney transplants among Black patients, with a 5.3 transplant increase per 1,000 listings. The study found that wait time modifications, required by a national policy, resulted in a 1.7-year gain in priority status for Black candidates.
Researchers from Institute of Science Tokyo developed 'tubuloids' to capture the slow progression of chronic kidney disease (CKD), replicating key features such as DNA damage, cellular senescence, inflammation, and fibrosis. This realistic platform provides a new way to develop and test treatments for millions globally.
Researchers used human-induced pluripotent stem cell-derived kidney organoids to model nephronophthisis, revealing the Hippo signaling pathway's role in fibrosis. Inhibiting this pathway with drugs like verteporfin shows promise as a treatment option.
A recent FAU Engineering study leverages quantum computing to enhance the accuracy of chronic kidney disease (CKD) diagnosis. The research team developed and compared two automated systems: Classical Support Vector Machine (CSVM) and Quantum Support Vector Machine (QSVM). CSVM achieved remarkable 98.75% accuracy, while QSVM reached 87....
The study found CKD affects nearly 800 million worldwide, with diabetes and high blood pressure driving the greatest loss of healthy years. Access to kidney replacement therapies remains limited, highlighting the need for preventive measures and equitable care.
Scientists have discovered that immune cells shed their glycocalyx layer to move into tissues, changing the understanding of inflammatory skin diseases like psoriasis. This finding may lead to new approaches in developing drugs targeting immune cell movement and treating infections and inflammatory diseases.
Researchers identified C-C chemokine ligand 5 (CCL5) as a key player in kidney injury and repair, with the molecule behaving both protectively and harmfully. The study suggests future drugs could target only its damaging effects, paving the way for more precise treatments for chronic kidney disease.
Researchers at Medical University of South Carolina develop a new approach to preventing lupus nephritis by improving kidney cell function. Exposure to serum from patients with lupus nephritis causes inflammation, but simultaneous exposure to L-sepiapterin reduces inflammation and enhances nitric oxide production.
QUT researchers create novel composite traits from UK Biobank data, identifying 50,000 biomarkers that outperform eGFR in detecting CKD. Their approach uncovers genetic signals missed by traditional methods.
A Berlin-led research team has discovered that a small population of immune cells called innate lymphoid cells (ILCs) trigger severe kidney inflammation in patients with lupus. ILCs, which are present in the kidneys, amplify organ damage when activated by NKp46 receptors.
New biomarkers have been discovered to improve the diagnosis and monitoring of lupus nephritis, a severe manifestation of systemic lupus erythematosus. The study identified six novel urine biomarkers that can detect even low concentrations of proteins in the urine.
A comprehensive review of targeted therapies for lupus nephritis discusses the challenges of current treatments and proposes strategies to overcome obstacles. Recent advancements in B-cell targeting and alternative approaches such as CAR-T cells are highlighted.
Treatment with obinutuzumab has been shown to preserve kidney function and prevent flares in patients with lupus nephritis. The addition of obinutuzumab to standard treatment reduced the risk of composite outcomes, such as death or treatment failure, by 60%.
A recent study found elevated TonEBP expression in patients with lupus nephritis, correlating with inflammatory cytokines and kidney damage. Suppressing TonEBP was shown to halt lupus progression and mitigate kidney damage in animal models.
Imaging mass cytometry showcases odd numbers of proteins in kidneys of lupus patients, identifying novel markers for disease. The study found decreased and increased disease markers pointing to renal disease, with potential enlargement of glomeruli in some patients.
A University of Houston research team has developed a new method for early diagnosis and monitoring of lupus nephritis using a smartphone-based test. The test assesses the levels of ALCAM protein in urine, showing high diagnostic accuracy for renal pathology activity in active lupus nephritis.
A prespecified subgroup analysis of East Asian adults with lupus nephritis found that belimumab added to standard therapy improved kidney outcomes significantly. The study also showed no new safety concerns were raised in the subgroup.
Researchers at the University of Houston have identified blood biomarkers predicting heart disease in lupus patients and urine biomarkers for diagnosing kidney inflammation in children with lupus. These findings hold promise for early preventive measures and improved treatment outcomes.
A new targeted therapy inhibits specific immune cells associated with lupus nephritis, improving kidney inflammation in animal models. Elevated levels of ALCAM molecules suggest a potential new path toward personalized medicine.
A new web-based application uses machine learning to predict lupus nephritis treatment response, considering various disease indicators. The tool may help physicians identify patients at risk of poor outcomes, enabling them to provide targeted care and preserve as much kidney function as possible.
A study published in Nature Communications reveals distinct urinary biomarker proteins for lupus nephritis in African American patients. The findings suggest that the ALCAM protein may be a promising therapeutic target. Researchers plan to conduct a longitudinal study to predict disease flares and improve treatment options.
A new study found an inverse association between socioeconomic status and certain kidney diseases. Researchers observed incremental increases in the incidence of lupus nephritis and ANCA-related glomerulonephritis with progressively lower income.
Researchers have identified C4BP as a promising therapeutic agent for autoimmune kidney disease, showing improved symptomatology in mice with lupus nephritis. The study demonstrates the immunomodulatory capacity of C4BP, transforming proinflammatory activity into anti-inflammatory and tolerogenic effects.
Scientists have identified two types of blood clotting proteins found in the urine of patients with lupus nephritis, which can serve as non-invasive biomarkers for early diagnosis and monitoring of the disease. The discovery may lead to improved clinical management and treatment responses.
A study found that cyclosporine significantly reduced proteinuria in patients with lupus nephritis, achieving higher remission rates compared to mycophenolate mofetil and azathioprine. After a 10-year follow-up, the majority of patients in the cyclosporine group achieved complete remission.
Researchers developed a new testing method using single-cell RNA sequencing to analyze individual cells in diseased organs, revealing genetic glitches that may allow for more effective treatment. The study found promising results in lupus patients and could potentially improve biopsy accuracy for other diseases.
A synthetic peptide has been found to directly disrupt destructive inflammation in the kidneys, enabling better recovery and maintaining important functions. The peptide reduced immune cell movement, resolved inflammation, and improved kidney function without increasing blood pressure.
A nationwide cohort study found that timely kidney transplant significantly increases survival in patients with lupus nephritis and end-stage renal disease. The study revealed a 70% reduction in overall risk of death, with benefits observed across various subgroups, including African Americans, Hispanics, Asians, and both sexes.
Researchers have developed a new treatment that delivers an inflammation inhibitor directly to the kidneys, reversing the course of destructive nephritis. The treatment restores mitochondrial function and reduces cell death, offering hope for patients with chronic kidney disease.
A team of engineers is creating a smartphone-based test kit to detect kidney inflammation in patients with Systemic Lupus Erythematosus. The test uses glow-in-the-dark nanoparticles to measure protein levels in urine, offering a non-invasive and quantitative solution for patients.
Researchers found that mesenchymal stem cells alleviate inflammation and nephritis in mice with SLE, suggesting a potential treatment for severe autoimmune diseases. The study showed that MSCs suppress T helper cell development, which helps to slow disease progression.
A biomedical engineer at UH is studying a potential treatment for lupus nephritis by targeting the interaction between three specific molecules. The goal is to determine if blocking this pathway can prevent kidney inflammation and failure.
Researchers identified gene variants associated with an increased risk of kidney problems in lupus patients, which could lead to better treatments to protect kidney health. The study found that variants in the ABIN1 gene were linked to an increased risk of lupus nephritis, a common complication of the disease.
The American College of Rheumatology has released new guidelines for the screening, treatment, and management of lupus nephritis. The guidelines include methods for identifying renal disease, newer therapies, and treatment of pregnant patients with kidney involvement. Patient survival rates are significantly lower when lupus nephritis ...
A new study finds mycophenolate mofetil superior to azathioprine as a maintenance therapy for lupus nephritis, with improved patient outcomes and reduced side effects. The study included 227 patients from 19 countries and showed that mycophenolate mofetil was more effective in treating the condition.
The current classification system for lupus nephritis is too detailed and may make it harder for clinicians to treat kidney problems in patients with lupus. A new study analyzing data from 86 patients found no significant difference in health outcomes between segmental and global forms of class IV lupus nephritis.
A decade of research has led to significant advances in treating lupus nephritis, with improved classification and new treatment regimens reducing side effects. New therapies targeting specific components of the immune system have also shown promise, including rituximab and ocrelizumab.
A new study published by the American Society of Nephrology suggests that having a history of lupus does not significantly increase the risk of developing lupus nephritis in recipients of a kidney transplant. The study found that lupus nephritis occurred in just 2.44% of patients, and was associated with only a 7% risk of organ loss.
The study found that mycophenolate mofetil was as effective as cyclophosphamide in treating lupus nephritis, but showed better results in certain racial groups. Patients may prefer mycophenolate mofetil due to its lack of fertility side effects.
Researchers at Vanderbilt University School of Medicine have discovered that inhibiting an enzyme called 11-beta-HSD2 blocks COX-2 activity in human and mouse colorectal tumor cells, potentially providing a new approach to preventing colorectal cancer. This finding is significant because long-term inhibition of 11-beta-HSD2 did not cau...
A study published in the Clinical Journal of the American Society Nephrology suggests that rituximab can significantly improve kidney health in patients with severe lupus nephritis. The immunosuppressive drug showed promise in reducing inflammation and improving renal outcomes in those who did not respond to conventional therapy.
A new treatment combining immunosuppressant drugs targeting different immune system parts improves remission rates and reduces side effects for patients with severe lupus nephritis. The therapy shows superior results compared to traditional treatments, achieving complete remission in 65% of patients within nine months.
Researchers at UT Southwestern Medical Center have identified four molecules in the urine of mice with lupus nephritis that may serve as potential biomarkers for early diagnosis. These molecules, including VCAM-1 and CXCL16, could help predict kidney disease in patients with lupus.
Researchers found that while both treatments showed promise, treatment 2 was associated with a higher risk of disease recurrence and shingles. The study suggests that patients should be thoroughly informed about the pros and cons of each treatment to make an informed decision.
A new study published in the New England Journal of Medicine suggests that CellCept, a potential treatment for lupus nephritis, holds promise for improving quality of life for those affected by severe kidney disease. The results offer hope for patients who currently suffer debilitating side effects from traditional treatments.
Researchers found that MMF was superior to traditional treatment in inducing complete remission and had fewer severe side effects. The new findings offer hope for improving quality of life for millions of people worldwide suffering from lupus.